Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Captafer is an iron-free oral food supplement designed to enhance the intestinal absorption of dietary iron. Developed by Medestea, it contains a standardized fraction of hydrolyzed sea fish cartilage (rich in glycosaminoglycans and oligosaccharides) along with a mixture of antioxidants and minerals, including Vitamin C, Vitamin E, Folic acid, Zinc, and Copper. The primary mechanism involves mimicking the "meat factor" to increase the bioavailability of non-heme iron by 3 to 5 times. It is primarily used as an alternative to traditional oral iron salts for treating iron deficiency anemia, particularly in patients with inflammatory bowel disease (IBD) who may not tolerate standard iron supplements due to gastrointestinal side effects or disease exacerbation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Captafer.